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causes more than 25 0000 annual deaths 
in the United States alone.[1] Despite 
significant efforts made for sepsis diag-
nosis, existing methods still suffer major 
shortcomings, including a long sample-
to-answer time, low sensitivity, and insuf-
ficient selectivity. For example, microbial 
culture to identify the source of infec-
tion, which is one of the gold standards 
of sepsis diagnosis, may take over 48 
hours for incubation, and false nega-
tive results (over 24%) are very common 
due to a low density of blood bacteria at 
the early stage of infection.[2] Without 
timely diagnosis and treatment, the condi-
tion can quickly deteriorate and result in 
septic shock that causes multiple organ 
dysfunction syndrome (MODS) or mor-
tality accompanied by severe systemic 
inflammation (Figure 1a). A therapeutic 
strategy guided by a biomarker accurately 
reflecting the presence and severity of the 
disease is a promising approach for sepsis 
management.[3,4]
Neutrophils are essential immune cells to combat microbial 
infections in the front line of defense.[5] One of the defense mech-
anisms of neutrophils involves cell death induced by the release 
of neutrophil extracellular traps (NETs), which form a meshwork 
of chromatin fibers mixed with granule-derived antimicrobial 
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1. Introduction
The human society has experienced a number of illnesses 
caused by bacterial infections throughout its entire history. As 
a potentially life-threatening form of infectious illness, sepsis 
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peptides and enzymes to kill bacteria extracellularly. Citrullina-
tion of histone H3 (CitH3), catalyzed by peptidylarginine deimi-
nase (PAD), has recently been identified to be involved in an 
early step in the NETs-induced cell death (NETosis) in response 
to severe infection (Figure 1b).[6] Serum levels of CitH3 are sig-
nificantly elevated with increasing severity of lipopolysaccharide 
(LPS)-induced septic shock.[7] Circulating CitH3 can be detected 
early and serve as a selective biomarker of septic shock, and 
administering a drug that diminishes or abolishes circulating 
CitH3 improves the survival of septic mice.[8] As such, CitH3 is 
a more promising biomarker to provide an early sign of septic 
shock and guide therapy than other biomarkers widely used to 
monitor severe infection and pro-inflammatory responses, such 
as procalcitonin (PCT), interleukin (IL-6), and IL-1β.[7,8] However, 
timely CitH3-guided sepsis management is prohibited by the 
lack of a technology enabling quick, sensitive, and accurate detec-
tion of the CitH3 biomarker at the point of care (POC).
Researchers have extensively explored POC biomarker anal-
ysis techniques using localized surface plasmon resonance 
(LSPR) sensors incorporating antibody-conjugated metallic nan-
oparticles.[9,10] These LSPR biosensors are advantageous for POC 
measurements[11–13] as they are label-free, robust, rapid, cost-
effective, and easy to integrate into miniaturized fluidic devices 
with simple optics.[14–16] They are also attractive for diagnosing 
and monitoring the trajectory of critically ill patients.[16,17] Our 
previous study[18] demonstrated that strategically integrating a 
LSPR biosensing layer above a molybdenum disulfide (MoS2) 
photoconductive channel allows for constructing a self-con-
tained photoelectronic protein biosensor. The small device archi-
tecture of this biosensor eliminates the need for large-volume 
off-chip detectors in signal transduction, such as charge-coupled 
devices (CCDs) and ultrahigh-resolution photospectrometers, 
thus potentially serving as a POC platform for CitH3-based early 
infection diagnosis. Unfortunately, this device still faces two 
major issues; (i) it cannot achieve sufficiently fast speed because 
of the significantly weak affinity of CitH3 to antibodies on the 
commercial market; and (ii) it falls short of reaching the highest 
sensitivity in CitH3 detection due to the unoptimized structural 
arrangement of gold nanoparticles on its LSPR biosensing layer.
Here, we report a highly miniature (2.5 × 2.5 µm2) biosensor 
device combining nanoscale plasmonic and photo electronic effects 
for detection of the CitH3 infection biomarker (Figure 1c,d). In this 
study, we constructed structurally optimized hemispherical gold 
nanoparticle arrays, namely “gold nanohemispheres (AuNHs)” 
(Figure 2a), using a highly scalable self-assembly material syn-
thesis technique. After functionalizing AuNHs with our lab-made 
high-affinity CitH3 monoclonal antibodies,[8] we incorporated 
them into the aforementioned LSPR-MoS2 device architecture.[18] 
The device was newly termed the “integrated nano optoelectronic 
biosensor (iNOBS)” and was shown to achieve optoelectronic 
detection of CitH3 and other sepsis-related biomarkers (IL-1β, and 
PCT) in serum at high sensitivity. The operation of iNOBS was 
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Figure 1. Neutrophil extracellular traps (NETs)-induced sepsis biomarker detected by integrated nano optoelectronic biosensor (iNOBS). a) Death 
count of patients in septic shock after intensive care unit (ICU) admission. b) CitH3 released into blood circulation upon neutrophil extracellular trap 
(NET)-induced immune cell death (NETosis) occurring in response to severe infection. CitH3 serves as a specific sepsis biomarker at an early stage 
of sepsis development. The 4 unique citrullinated molecular sites (4 Cits) of CitH3 are used for high-affinity binding with the custom-made antibody 
in this study. c) Schematic of the iNOBS device architecture and operation; i) loading of a sample (e.g., serum) of small volume (≈2.5 µL) onto a 
polydimethylsiloxane (PDMS) microfluidic well (scale bar = 200 µm), ii) settling of biomarker molecules onto the device surface (scale bar = 500 nm). 
d) Photo image of the iNOBS chip (scale bar = 15 mm).
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supported by the broadly ranged photoresponsivity of a few-layer 
MoS2 photoconductive channel. The AuNH surfaces of iNOBS 
achieved a large electric field enhancement for incident light at a 
biologically behind near-infrared (NIR) wavelength of λ = 650 nm. 
Taken together, the iNOBS-based label-free binding assay enabled 
CitH3 detection with a LOD of 0.87 pg mL−1 (56 fM), which is 
250-fold smaller than that of commercial ELISA, a large dynamic 
range of 105, a short sample-to-answer time of 20 min, and a small 
sample volume of 2.5 µL. The accuracy of our iNOBS-based CitH3 
measurement was confirmed by ELISA over a wide range from 
10−2 to 101 ng mL−1. With the remarkable label-free biosensor, we 
established the ability of continuously monitoring the time-varying 
CitH3 biomarker profiles in the circulation system of a sepsis 
mouse model.
2. Results and Discussions
2.1. Plasmo-Photoelectronic Nanostructure and Characterization
The iNOBS device architecture has three main components: 
(i) a bio-tunable nanoplasmonic optical filter (Bio-NOF) layer, 
which is a thin (100 µm) SiO2 substrate covered by gold nano-
particles (AuNPs); (ii) a few-layer MoS2 photoconductive channel 
underneath the Bio-NOF layer; and (iii) a polydimethylsiloxane 
(PDMS) layer with a microfluidic well above the Bio-NOF layer. 
Only a small fraction of incident light transmits through the 
Bio-NOF layer initially and reaches the MoS2 photoconductive 
channel, which yields a small baseline photocurrent signal (Iph_0) 
(Figure 2a). The resonant behavior of the conduction band elec-
tron oscillations near the surface of the optically excited nanopar-
ticles (i.e., LSPR effect) varies with a local refractive index (nm) 
change brought by the surface binding of protein molecules.
As illustrated in Figure 2b, constructing highly packed, uni-
form AuNPs on the Bio-NOF layer is necessary to achieve high 
sensitivity in CitH3 measurement. A uniform distribution of 
AuNPs results in a narrow LSPR spectrum curve. Our previous 
study[18] detected IL-1β, a pro-inflammatory cytokine, using a 
similar device to iNOBS. The AuNPs on the Bio-NOF layer in 
this device were deposited by a simple, cost-effective method 
of casting a droplet of colloidally suspended nanoparticles (i.e., 
drop-casting method). The arrangement of the drop casting-
deposited AuNPs showed poor uniformity.[18] However, this was 
still acceptable in the previous study because strong antigen-
antibody affinity was found for IL-1β.  In contract, we expect 
that CitH3 measurement with weak antibody affinity inherently 
limits a local refractive index shift in the presence of the analyte 
at a given concentraion. To address this issue, we structurally 
engineered self-assembled AuNH arrays with an optimal inter-
particle distance and density to maximize the sensitivity of our 
measurement in this study (Figure S1, Supporting Information).
Figure 2c shows a scanning electron microscope (SEM) image 
of the constructed AuNHs with highly enhanced uniformity 
and density. The arrayed AuNH arrangement has a surface den-
sity of DAuNH ≈ 800 particles µm−2, a particle size of dAuNH = 
42 nm ± 10%, and an interparticle distance of lAuNH ≈ 43 nm 
with a standard deviation less than 30% (Figure 2d). Compared 
to the AuNP arrangement prepared by the drop-casting method, 
the arrayed AuNH arrangement showed a five times narrower 
distribution in both particle size and interparticle distance. Our 
finite element analysis predicted a strong electric field confined 
between two neighboring AuNH particles (Figure S2, Sup-
porting Information). We measured LSPR spectra for both AuNP 
and AuNH structures with similar values of particle density 
(≈800 particles µm−2) (Figure 2e). The spectrum of the arrayed 
AuNH arrangement yielded a narrower LSPR shape with a peak 
at λ = 650 nm. We measured the base photocurrent Iph_0 for two 
iNOBS devices, one with a Bio-NOF layer incorporating the drop 
casting-deposited AuNPs and the other with a Bio-NOF layer 
incorporating the arrayed AuNHs. Under laser light illumination 
at λ = 650 nm, we observed Iph_0 = 0.77 µA and Iph_0 = 0.1 µA at an 
voltage applied across the MoS2 channel (a drain-source voltage) 
of Vds = 1 V for the former (AuNP) and latter (AuNH) devices, 
respectively (Figure 2f). The significantly smaller Iph_0 value for 
the AuNH device indicates that our self-assembly-based structural 
engineering approach served well for constructing a Bio-NOF layer 
with much higher nanoplasmonic optical filtration efficiency.
We fabricated the photoconductive few-layer MoS2 channel on 
a thermally oxidized silicon substrate using our micro-printing 
method (Figure 3a and Figure S3, Supporting Information).[19] A 
pair of Ti/Au pads laterally sandwiching the MoS2 channel served 
as the electrode contacts for reading sensor signals (drain cur-
rent, Ids) at Vds (Figure S4, Supporting Information). The effec-
tive channel length was measured to be ≈1 µm, which ensured a 
highly uniform crystal structure for the MoS2 sensing region. The 
as-printed MoS2 channel had a uniform thickness of 14.5 nm with 
± 5% tolerance along the path that was determined by atomic force 
microscopy (AFM) (Figure 3b and Figure S5, Supporting Informa-
tion). This allowed us to operate the iNOBS device with the suf-
ficiently high photo responsivity of the few-layer MoS2 channel. 
The laser illumination a λ = 650 nm resulted in 100 times photo-
enhancement (Figure S6, Supporting Information).
We characterized the LSPR shift of the “bare” arrayed AuNHs 
prior to antibody conjugation in response to the changing nm 
of a surrounding medium (glycol-water solution). Additionally, 
we measured the photoresponsivity (R = Iph/Pin, where Pin is 
power density of incident light.) spectrum of the MoS2 channel 
(Figure 3c and Table S1, Supporting Information). The value of 
nm was varied with the glycol-to-water ratio in the medium (see 
Experimental Section). We observed a reasonably good overlap 
between the spectra of the photoresponsivity of the MoS2 
channel and of the LSPR of the arrayed AuNHs, and the illumi-
nation optical band (λ = 650 nm ±10%). Using an iNOBS device 
with the bare AuNHs, we measured the variation of Iph with nm  
and compared it with the LSPR peak shift (Δλmax) character-
ized above (Figure 3d). The measured Iph linearly correlates to 
Δλmax (R2 = 0.9986), which indeed confirmed that LSPR-shift 
was responsible for the iNOBS photocurrent signal change 
(Table S2, Supporting Information). We also provide a compar-
ison of LSPR structures in Table S3, Supporting Information.
2.2. High-performance Infection Biomarker Detection
Our study functionalized the AuNHs of our device with a new 
CitH3 monoclonal antibody (Figure 4 and see Experimental 
 Section). Commercially available CitH3 monoclonal antibodies 
bind to histone H3 only at N-terminal with 3 citrullinated sites 
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(3 Cits) catalyzed by PAD4 alone. This results in limited antibody 
affinity. In contrast, our antibody was designed in our lab and 
synthesized in a custom-made manner so that it can tightly 
interact with 4 unique molecular sites (4 Cits) citrullinated by 
PAD4 and PAD2 (Figure 1b). Thus, the novel CitH3 antibody 
has a higher affinity, in addition to specificity, compared to 
conventional antibodies. Additionally, our recent study shows 
that our anti-CitH3 antibody can significantly improve survival 
in a mouse model of sepsis.[20]
The iNOBS device enabled simpler and more miniatur-
ized biomarker detection as compared to a conventional LSPR 
biosensing setup (Figure 4a) (see Experimental Section). 
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Figure 2. Bio-tunable nanoplasmonic optical filter (Bio-NOF). a) i) Bio-NOF consisting of anti-antibody-conjugated gold nano-hemispheres (AuNHs) 
on a thin SiO2 substrate (scale bar = 40 nm), ii) cross-sectional schematic of the iNOBS device architecture. b) Conceptual illustration showing the 
impact of the density and uniformity of the gold nanoparticle arrangement on the LSPR spectrum of Bio-NOF and the Iph-Vds curve of iNOBS. i) high-
density, high-uniformity arrangement expected to yield a sharp LSPR spectrum curve and a larger photocurrent increase (ΔIph = Iph – Iph_0) in response 
to a local refractive index change. ii) high-density, low-uniformity arrangement expected to yield a broad LSPR spectrum curve and a smaller value of 
ΔIph . iii) low-density, high-uniformity arrangement expected to yield weak LSPR-based photoabsorption and a smaller value of ΔIph. c) Highly scalable 
self-assembly of optimally engineered gold nanostructural arrays; schematics and scanning electron microscopy (SEM) images of i) drop casting-
deposited AuNPs, ii) self-assembled arrayed AuNHs (scale bar = 500 nm), d) Analyzed interparticle distance (IAuNH) and size distribution (dAuNH) of 
arrayed AuNHs. e) LSPR spectra of drop casting-deposited AuNPs and the arrayedAuNHs. f) Iph-Vds curves for the baseline photocurrent Iph_0 of iNOBS 
with drop casting-deposited AuNPs and arrayed AuNHs of similar particle density (≈800 particles µm2).
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Before conducting the iNOBS assay illustrated in Figure 4b, 
we first verified the performance of the Bio-NOF layer for 
CitH3 quantification using a commercial photo spectrometer 
(Experimental Section). In this test, we loaded a CitH3-spiked 
serum sample onto the Bio-NOF layer with CCitH3 varying 
from 10−4 to 101 ng mL−1 (Figure S7, Supporting Informa-
tion). We observed a total peak wavelength shift of Δλmax ≈ 
10 nm when CCitH3 decreased from 101 to 10−2 ng mL−1. This 
setup detected no noticeable peak wavelength shift for CCitH3 
< 10−2 ng mL−1. With our observation here, we confirmed that 
the optical transmission of the Bio-NOF layer was tuned with 
the LSPR spectral shift accompanying the variation of CCitH3.
Figure 4c plots transient curves of the iNOBS photocurrent 
signal ΔIph (t) = Iph (t) – Iph0 as functions of the incubation time t 
measured at Vds = 1.0 V for CCitH3 between 10−4 and 101 ng mL−1 
(the curve at CCitH3 = 0 is the baseline). With CCitH3 reaching the 
lower (10−4 ng mL−1) and upper (101 ng mL−1) bounds, the 
ΔIph value saturated at ≈1.2 µA and ≈1.7 µA, respectively, 
within 20 minutes after loading a serum sample. The CCitH3 
value in a given sample can be quantified from the normal-
ized photocurrent variation ΔIph/Iph0. Figure 4d shows the 
standard calibration curve of the iNOBS device with CCitH3 
varying from 10−4 to 101 ng mL−1. The curve has a sigmoidal 
shape that is typically observed when antibody-antigen binding 
reactions are quantified at the full dynamic range.[21] The weak 
signal at the low concentration range becomes buried in the 
background noise. The binding sites on the sensor surface 
becomes saturated with the analyte molecules at the high 
concentration range. Thus, these two extreme ranges result 
in the lower and upper saturations of the standard curve. 
From this curve, we found that the device achieved a LOD of 
0.87 pg mL−1 with a large (105) dynamic range. The curve also 
exhibits a trend similar to that obtained from the LSPR peak 
position (λLSPR) measured by the LSPR biosensing setup using 
the commercial photo spectrometer in Figure S7, Supporting 
Information. While this LSPR biosensing setup failed to dis-
tinguish the peak shift for CCitH3 < 10−2 ng mL−1 owing to its 
limited spectral resolution (≈0.1 nm), the iNOBS device was 
still able to capture a noticeable change of Iph resulting from 
the small LSPR peak shift even at CCitH3 < 10−2 ng mL−1.
2.3. Validation of the iNOBS Assay Using Clinical Samples
Using the iNOBS device, we performed sepsis biomarker anal-
ysis for serum samples extracted from living mice (Figure 5). 
A regression line for correlating the results from iNOBS and 
commercial ELISA assays measuring CitH3 was obtained for 
the sample samples (Figure 5a and Methods). The correlation 
shows a strong linear relationship (R2 = 0.9968). The iNOBS 
assay achieved a LODiNOBS as small as 0.87 pg mL−1 whereas 
the ELISA exhibited an LODELISA of 232 pg mL−1 (Table S4, 
Supporting Information). Here, the ELISA test employed a 
commercial CitH3 monoclonal antibody (Cayman Chemical, 
Small 2020, 16, 1905611
Figure 3. Integrated plasmonic nanostructure array and MoS2 channel. a) Optical micrographs of a 14 nm thick, 1 µm long MoS2 channel with elec-
trodes (scale bar = 10 µm). b) Atomic force microscope image of the MoS2 layer on a SiO2 layer (100 nm thickness) (Cross-sectional profiles along 
the white lines from (i) to (vi) are shown in Figure S5, Supporting Information). c) LSPR spectra of the Bio-NOF with the arrayed AuNHs (arbitrary 
unit) for the different values of the environmental (bulk) refractive index (nm) varying from 1.33 to 1.47 and photoresponsivity spectrum of the MoS2 
photoconductive channel, both compared to the spectral band of the incident light (λ ≈ 650 nm). d) LSPR peak wavelength shift (Δλ) of the arrayed 
AuNHs versus Iph of the MoS2 photoconductive channel at Vds = 1.0 V as a function of nm.
1905611 (6 of 10)
www.advancedsciencenews.com
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.small-journal.com
Ann Arbor, MI, USA). Such a comparison shows that the 
iNOBS device has a superior concentration sensitivity (or LOD) 
for CitH3 over 250 times higher than that of the ELISA assay.
Subsequently, we performed a control experiment to test 
the iNOBS’s selectivity to the target biomarker,, i.e., CitH3, in 
comparison with other four different background biomarkers 
relevant to sepsis (i.e., PCT, IL- 1β, IL-6, and TNF-α) in 
mouse serum with their concentrations ranging from 10−4 to 
101 ng mL−1 all together (Figure 5b). In this test, we observed 
no noticeable changes in ΔIph/Iph0 with respect to the con-
centrations of any biomarkers other than CitH3. This result 
indicates negligible cross-reactivity among these biomarkers 
and therefore proves the capability of the iNOBS assay. Our 
device enabled highly selective detection of target biomarker 
molecules.
Furthermore, we applied the iNOBS device in the measure-
ment of circulating CitH3 in a living mouse treated by cecal 
ligation and puncture (CLP)-induced sepsis.[22,23] The CLP 
procedure mimics a ruptured appendix or perforated diver-
ticulitis in human and allows for identifying an irreversible 
stage of sepsis where the excision of necrotic tissue cannot 
improve survival.[24,25] Therefore, CLP has been recognized as 
a standard animal model for sepsis study (Figure 5c).[26] Based 
on previous studies reporting that mortality was dramatically 
changed within 24 h,[8,27] we measured CitH3 for serum sam-
ples collected from the mouse at 0, 12, and 24 h after the CLP 
procedure (Experimental Section). For comparison, a western 
blot was also performed for the same mouse serum samples. 
The serum collected at 0 h did not show any signature of 
CitH3 in both the iNOBS assay and the western blot measure-
ment. The CitH3 level in serum reached ≈0.11 ng mL−1 at 12 h 
after the CLP insult, and further increased to ≈0.89 ng mL−1 at 
24 h. The western blot images qualitatively matched the iNOBS 
assay data. Importantly, our iNOBS assay provided consistent 
quantitative data with a 100-fold faster measurement speed in 
comparison with the conventional western blot technique.
2.4. Multi-time Point Measurement of Infection Biomarker 
Profile for Living Mice
Finally, we demonstrated iNOBS-based multi-time-point 
detection of biomarkers using different mouse models 
(Figure 6). We first obtained time-series profiles of CitH3 
Small 2020, 16, 1905611
Figure 4. Nano-plasmo-photoelectronic detection performance of iNOBS. a) Setups of i) LSPR spectroscopy measurement (L1: darkfield condenser, 
L2: objective lens, M1-3: mirror 1–3, CCD: charge-coupled detector, dashed line box: spectrometer) and ii) iNOBS measurement based on LSPR-MoS2 
nano-plasmo-photoelectronic signal transduction (BF: band path filter). b) Binding of CitH3 antigen molecules onto the antibody-conjugated AuNHs 
continues to decrease the LSPR-induced absorption of incident light at the Bio-NOF layer until the system reaches equilibrium. This is translated 
to a photocurrent increase ΔIph in the MoS2 channel over time. c) ΔIph at Vds = 1.0 V as a function of the incubation time after sample loading with 
CCitH3 ranging from 10−4 to 101 ng mL−1. d) Standard calibration curves (photocurrent change (ΔIph/Iph_0) versus CCitH3) obtained using the iNOBS 
(LSPR-MoS2) device and the LSPR spectroscopy setup.
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and two other biomarkers (IL-1β and PCT) for a LPS-injected 
living mouse over 12 h, at which the animal died (Figure 6a). 
The measurements were repeated with multiple devices 
(n = 5). After the injection of LPS at ≈1.2 ng mL−1, we observed 
that CCitH3 in the endotoxic mouse monotonically increased 
over time, rapidly reached a high level over 1 ng mL−1 
at 6 h, and steadily increased to 1.385 ng mL−1 at 12 h. 
The PCT concentration (CPCT) was as low as 0.075 ng ml−1 
at 6 h and only increased to 0.078 ng mL−1 at 12 h (20 times 
smaller than the CCitH3 value). The IL-1β concentration (CIL-1β) 
in the sample was ≈1.031 ng ml−1 at 3 h but finally decreased 
to ≈0.758 ng mL−1 at 12 h after repeating fluctuations. How-
ever, the CCitH3 profile followed the endotoxic shock of the host 
consistently increasing from the initial point of LPS injection 
up to the endpoint of the animal life. As another approach 
of demonstration, we also successfully monitored the endo-
toxemia of another mouse model treated by YW3-56, an anti-
cancer PAD inhibitor, via intraperitoneal injection (Figure 6b). 
As expected, our data showed that the treatment with YW3-56 
significantly decreased CCitH3 and CIL-1β as compared to those 
insulted only with LPS. Finally, we could monitor the dynamic 
response of the level of the biomarkers in such a shorter time 
interval which cannot be achieved by the current gold standard 
ELISA method.
Furthermore, we employed two different mouse models for 
the iNOBS assay: LPS-induced shock (LPSS) as an infectious 
model and hemorrhagic shock (HS) (30% blood loss) as a non-
infectious model, and replicated our recent finding that CitH3 
is detected in LPSS but not in HS (Figure 6c,d).[8] We measured 
the level of the target biomarkers in blood samples at 0, 0.5, 
and 12 h after LPS or HS insult (see Experimental Section). 
LPS led to an increase of CCitH3 in the LPS-insulted mice from 
0.022 to 1.137 ng ml−1 at 0.5 and 12 h, respectively; while in the 
HS mice, very low levels of CCitH3 (from 0.001 to 0.031 ng ml−1) 
were detected. The CCitH3 levels at 0.5 and 12 h clearly distin-
guished the non-infectious and infectious systemic inflamma-
tion development with a high sensitivity. The CIL-1β value also 
increased distinctively from 0.5 to 12 h after LPS insult. How-
ever, we observed in Figure 6a that the IL-1β levels showed fluc-
tuation over time. Therefore, IL-1β alone could hardly reflect 
the course of endotoxic shock. The concentration of PCT was 
too low to be sensitive for differentiating between LPS-induced 
endotoxic shock and hemorrhagic shock.
LPS is a central mediator that plays a critical role in the acute 
pathogenesis of endotoxemia and endotoxic shock.[7] LPS can 
stimulate nuclear translocation of PAD and induce neutrophil 
extracellular trap (NET) formation. CitH3, as a component of 
the NETs, is released into circulation meanwhile. The temporal 
profile of the CitH3 biomarker measured over the lifetime 
of the endotoxic mouse model may well represent the time-
course development of the biological process responsible for 
CitH3 release from NETs into circulation. Generally, to provide 
timely and precise treatment of sepsis, it is critical to discrimi-
nate infectious inflammation from non-infectious inflamma-
tion at an early stage. However, they both represent alterations 
during common inflammatory stress responses and can be 
hardly differentiated well at an early state through conventional 
assay processes.[28] The iNOBS data obtained for two different 
types of mouse models indicate that CitH3 measurement can 
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Figure 5. iNOBS-based sensitive and selective sepsis biomarker detec-
tion using mouse models. a) Linear regression between iNOBS assay 
and ELISA data for the same serum samples spiked with CitH3 at CCitH3. 
ranging from 10−2 to 10 ng mL−1. The iNOBS assay was performed 
≈20-times faster and 250-times more sensitive than ELISA. b) Photo-
current signal (ΔIph/Iph0) data of the iNOBS obtained for a mixture of 
IL-1β, CitH3, IL-6, TNF-α, and PCT in healthy (sham) mouse serum at 
various concentrations (n = 6). The concentrations for the background 
biomarkers: IL-1β; IL-6; TNF-α; and PCT were varied so that their values 
were identical with that of CitH3 for each measurement. The data show 
high selectivity of the device to CitH3 as the signal for CitH3 is distinctly 
higher than those for the other biomarkers with a statistical significance 
(p ≤ 0.01). c) CLP mouse model study. CLP treated mouse as a “gold 
standard clinical sepsis model” which mimics human sepsis develop-
ment. Comparison of circulating CitH3 detected by i) western blot and ii) 
the iNOBS assay at 0, 12 and 24 h after CLP treatment.
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significantly distinguish between infectious and non-inflamma-
tory responses.[8,29]
3. Conclusions
Unlike cancer and other chronic diseases, infection-induced 
sepsis can rapidly and dynamically evolve. Management of severe 
sepsis imposes stringent requirements on diagnosis in terms of 
speed and sensitivity.[30] In this study, we developed a miniatur-
ized biosensor platform for detecting CitH3, a circulating sepsis 
biomarker released by neutrophils upon the first-line immune 
defense activity against infection. The biosensor monolithically 
integrated highly ordered, uniform, and packed self-assembled 
antibody-functionalized AuNH arrays and a highly photorespon-
sive few-layer MoS2 photoconductive channel into a small chip. 
We functionalized the AuNH arrays with a new high-affinity 
CitH3 monoclonal antibody developed by our lab. The unique 
combination of the nanoscale plasmonic structure, antibody, and 
two-dimensional (2D) material permited self-contained photo-
electronic label-free detection of serum CitH3 with high speed, 
high sensitivity, high accuracy, and a large detection range. This 
study applied the remarkable performance of the iNOBS to dem-
onstrate our capability of monitoring circulating CitH3 and other 
biomarkers in situ in a living mouse in the sepsis mouse model 
after LPS-induced endotoxic shock. From its biological basis and 
measured time-course profile, CitH3 is expected to provide a 
more accurate signature of infection-induced inflammation than 
PCT, which has been used in the conventional clinical diagnosis 
of sepsis. Recognizing the heterogeneity of septic conditions 
and inter-patient variability, there is a need for shifting clinical 
management of infections towards personalized treatment.[31,32] 
The material processing used for the iNOBS construction is 
scalable for a fully standalone biosensor module for massively 
parallel analysis of multiple biomarkers at the point of care. The 
highly miniature iNOBS device may be eventually incorporated 
into a fully handheld portable POC diagnostic module without 
requring any bulky off-chip signal reader or instrument. This 
module would enable clinicians to monitor temporal biomarker 
profiles of patients in real-time and facilitate a biomarker-guided 
precision/personalized therapy of infections in a timely manner.
4. Experimental Section
Chemicals: 10-carboxy-1-decanethiol (C-10), Bovine serum albumin 
(BSA), Deoxyribonuclease (DNase), and Dimethyl sulfoxide (DMSO) 
Figure 6. Multi-time-point CitH3 measurement for a living mouse with the iNOBS device. a) Time-course profiles of circulating CitH3, PCT, and IL-1β 
in a living mouse at 0, 1, 3, 6, 9, and 12 h after LPS injection. At each measurement time point, a serum sample with a volume of 7.5 µL was collected 
from the mouse tail. The values of the biomarker concentrations were extracted from the obtained calibration curve (Figure S8 and Table S5, Supporting 
Information). b) Time-course profiles of circulating CitH3, PCT, and IL-1β for a living LPS-injected mouse under treatment with YW3-56, an anticancer 
PAD inhibitor. c) Illustration of neutrophil behaviors in LPSS and HS models. CitH3 is a specific biomarker used to distinguish the LPS condition from 
the HS condition. d) CCitH3, CPCT, and CIL-1β measured for LPS and HS mouse models (n = 20, *p < 0.005 and **p < 0.05). In the test, the HS mouse 
was subjected to 30% blood loss without resuscitation, and its blood samples were collected at 0, 0.5, and 12 h after the HS procedure.
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were purchased from Sigma Aldrich. Polystyrene-b-poly(2-vinylpyridine) 
(PS-bP2VP) (S units: 213000; VP units: 153000) was purchased from 
Polymer Science. 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC) 
and N-hydroxysuccinimide (NHS) were purchased from Thermo Co. Ltd. 
IL-1β and the anti-IL-1β antibody were purchased from Life Technologies, 
Frederick, MD. PCT was purchased from ProSpec BiO and the anti-PCT 
antibody was purchased from Lifespan Biosciences. The high-affinity 
CitH3 monoclonal antibody was designed by us and generated in 
ProMab Biotechnologies, Inc. (Richmond, CA). YW3-56 was purchased 
from Cayman Chemical. Polydimethylsiloxane (PDMS) elastomer and 
curing agent were purchased from Corning. Nano-pure deionized (DI) 
water (18.1 MΩ-cm) was produced in-house.
Animals: All animal experiments were conducted in compliance 
with the guidelines approved by the Animal Review Committee at 
the University of Michigan. Male C57BL/6J mice (9–10 weeks old) 
were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice 
were housed for at least 3 days before any procedure.
Few-layer MoS2 photodetector channel fabrication: We fabricated A 
few-layer MoS2 photoconductive channel on a SiO2/Si substrate using a 
micro-printing method (Figure S3) (see Supporting information).[33]
Au nanoparticle Array Synthesis and Characterization: Arrayed AuNHs 
were fabricated as the surface parts of the Bio-NOF layer by controlling 
the surface energy using block copolymer (BCP) chemistry (see 
Supporting information).
LSPR spectroscopy and optical properties: The LSPR properties of 
gold nanoparticle-deposited surfaces were characterized by photo 
spectroscopy. To confirm the uniformity, LSPR spectral measurement 
was repeated for different surface locations of the Bio-NOF layer by 
automated positioning with a motorized stage. The LSPR sensitivity of 
the Bio-NOF layer to a bulk refractive index change was characterized 
by loading a water-glycol solvent mixture onto the AuNH array surface 
at different mixing ratios. The figure-of-merit (FOM) of the LSPR-based 
refractive index sensing was calculated for the Bio-NOF layer by dividing 
the refractive index (RI) unit by the full width at half maximum (FWHM) 
of the measured LSPR spectral curve.
Measurement Optoelectronic Performance: All the photocurrent 
measurements were performed using a semiconductor parameter 
analyzer (HP-4145B). Our measurements used a 650-nm laser light 
source (power density: 2.4 mW). The baseline photocurrent signal of the 
device was calibrated. The power density of light transmitting through 
the Bio-NOF layer was measured using a power meter (Newport, 843-R).
Antibody Conjugation on Au Nanoparticle Array: The arrayed AuNHs 
were functionalized via self-assembled thiolate alkane 10-carboxy-1-
decanethiol (HS-(CH2)10-COOH) linkers.[16] After a surface cleaning 
process, a mixture of 0.4 M EDC and 0.1 M NHS at a 1:1 volume ratio 
was loaded onto the functionalized AuNHs. Then, an antibody buffer 
solution was loaded and incubated to conjugate the AuNHs with anti-
CitH3 antibody molecules.
Integration of AuNH-deposited Bio-NOF Layer and Few-layer MoS2 
Photoconductive Channel: After preparing the AuNH-deposited Bio-NOF 
layer and the atomically layered MoS2 photoconductive channel 
individually, we integrated them into a single on-chip device platform 
(see Supporting information).
Optoelectronic Biomarker Detection: The antibody-conjugated AuNH 
surfaces were treated with 10 µL of 1% BSA in a 1 × PBS blocking buffer 
to suppress the non-specific binding of background molecules in serum. 
The AuNH surfaces were thoroughly washed using 1 × PBS to remove 
excessive reagents and background molecules. Then, a DNase-treated 
serum sample was loaded into the detection chamber. After washing 
processes, the photocurrent signal of the iNOBS device was measured 
in a detection chamber where temperature and pressure were well 
controlled.
Near-field Electromagnetic Radiation Calculation: To obtain near-field 
electromagnetic radiation around an AuNH structure, we solved the 
Helmholtz wave equation based on a finite element analysis method 
(FEA, COMSOL Multiphysics software) (see Supporting information).
Enzyme-linked Sandwich Assay (ELISA): ELISA is the current gold 
standard method to quantify CitH3 in a serum sample. A 96-well plate of 
CitH3 ELISA kit was developed in our laboratory as described previously 
(see details in Supporting information).[8]
Western Blotting: Mouse serum was diluted with normal saline at 
1:1 ratio (15 µl serum + 15 µl normal saline) and added a 6 µL buffer. 
The prepared solution was denatured and separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred 
to nitrocellulose membrane. The membrane was probed with an anti-
CitH3 polyclonal antibody (1:1000 diluted; ab5103, Abcam, Cambridge, 
MA, USA) and an anti-rabbit secondary antibody (1:3000 diluted; 
ab97051, Abcam, Cambridge, MA, USA). Ponceau S staining served as 
a control for equal loading.
Cecal Ligation and Puncture (CLP): Male mice (25-30 g) underwent 
the standardized CLP procedure as previously described.[34] In our 
experiments, 75% of the cecum was ligated. After that, the cecum was 
perforated by a single puncture midway between the ligation and the 
tip of the cecum with a 21-G needle. After removing the needle, feces 
were extruded. The cecum was relocated, after that the fascia, abdominal 
musculature, and peritoneum was closed. The skin was also sutured. 
The sham mice were anesthetized and underwent laparotomy without a 
puncture or cecal ligation and served as the control.
Lipopolysaccharides (LPS)-induced Endotoxic Shock: LPS (35 mg kg−1) 
was injected into the mice intraperitoneally. Blood was collected at 
designated time points after LPS insult (n = 3/time point). Mice without 
any insult or treatment served as normal controls (n = 3/time point). For 
the treatment control, YW3-56 (5 mg kg−1; dissolved in DMSO vehicle) 
was intraperitoneally injected into mice after LPS.
Hemorrhagic Shock (HS): The procedure of hemorrhagic shock 
was performed as previously described.[8] Briefly, male mice were 
anesthetized with 5% isoflurane and maintained with 2% isoflurane. 
With the heart rate and blood pressure being monitored by Ponemah 
Physiology Platform (Ground Instrument Systems, Valley View, OH), 
the femoral artery of mice was cannulated with polyethylene 10 tubing 
(PE10, Clay Adams, Sparks, MD). Hemorrhagic shock with 30% blood 
loss was accomplished as described previously.[8] Animals from sham 
group received all procedures except cannulation and hemorrhage. The 
mice were sacrificed, and blood was collected at designated time points 
(n = 3/time point). Sham mice were performed the same procedures 
without being cannulated or subjected to hemorrhage (n = 3/time 
point). The serum samples were prepared by centrifuging the blood for 
20 minutes at 2000 × g.
Data Analysis: Results were presented as mean ± standard deviation 
(SD). Differences among no less than 3 groups were assessed by 
one-way analysis of variance (ANOVA), followed by Bonferroni post hoc 
testing for multiple comparisons. Student’s t-test was performed to 
determine the differences between the two groups.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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